Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224949 · ClinicalTrials.gov registry record
Comparison of ALD, NASH, and Healthy Control Patients
A clinical trial of ALD - Alcoholic Liver Disease, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT03224949: Recruiting study of ALD - Alcoholic Liver Disease, sponsored by The Cleveland Clinic.
NCT03224949 is a study of ALD - Alcoholic Liver Disease that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03224949, a study of ALD - Alcoholic Liver Disease, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in the translation of basic research advances to the clinic. The purpose of the Clinical Core component of the P50 Northern Ohio Alcohol Center (NOAC) is to provide biological samples (plasma/serum, buffy coats, and urine) from patients with different stages of alcoholic liver disease, as well as healthy control subjects, to members of the NOAC. These samples can then be used to test specific hypotheses related to the presence of specific biomarkers in the serum, functional immune activity in PBMCs and/or genetic polymorphisms that may predict severity of disease, short- and long-term morbidity and mortality and/or responsivity to specific therapeutic interventions commonly used in clinical practice. This study is building on the established biorepositories and the diversity of outstanding clinical expertise at the Cleveland Clinic. This biorepository included clinical samples (plasma, serum, buffy coats, and urine) from patients with different stages of ALD and subjects who are heavy drinkers without ALD, recruited from the Cleveland Clinic alcohol use disorder treatment clinic. This study will be responsible for collecting more data to help build the CCF-ALD biorepository via subject recruitment and communication and specimen collection.
Primary Outcome
The goal of this study is to create a biorepository of samples from patients with different types of liver disease compared to each other and healthy controls
Conditions Studied
Interventions
- OTHER Blood draw
Study Locations (1)
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2028-09-30 |
What NCT03224949 shows while recruiting
NCT03224949 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with ALD - Alcoholic Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT03224949 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03224949 about?
NCT03224949 is a clinical study titled "Comparison of ALD, NASH, and Healthy Control Patients". The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in the translation of basic research advances to the clinic. The purpose ...
What is the current status of trial NCT03224949?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2017-06-19. Estimated completion is 2028-09-30.
What conditions does trial NCT03224949 study?
This clinical trial studies the following conditions: ALD - Alcoholic Liver Disease.
What interventions are being tested in trial NCT03224949?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT03224949?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03224949 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI